Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Glez-Vaz J, Azpilikueta A, Olivera I, Cirella A, Teijeira A, Ochoa MC, Alvarez M, Eguren-Santamaria I, Luri-Rey C, Rodriguez-Ruiz ME, Nie X, Chen L, Guedan S, Sanmamed M, Gracia J, Melero I. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. Journal For ImmunoTherapy Of Cancer 2022, 10: e003532. PMID: 35236742, PMCID: PMC8896037, DOI: 10.1136/jitc-2021-003532.Peer-Reviewed Original ResearchConceptsMouse CD8 T cellsCD8 T cellsChimeric antigen receptorT cellsCD137 costimulationHuman CD137Surface expressionAnti-CD137 monoclonal antibodiesCAR-transduced T cellsCostimulatory molecule CD137Sequential plasma samplesCAR T cellsBasis of efficacyMouse tumor modelsProtein expression levelsCD137 agonistsSoluble CD137First patientSyngeneic tumorsAgonist agentsPharmacodynamic biomarkersClinical trialsPlasma concentrationsDynamic biomarkersSCD137
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply